000078348 001__ 78348
000078348 005__ 20200117221641.0
000078348 0247_ $$2doi$$a10.1016/j.schres.2017.06.032
000078348 0248_ $$2sideral$$a105319
000078348 037__ $$aART-2018-105319
000078348 041__ $$aeng
000078348 100__ $$aBioque, M.
000078348 245__ $$aEvolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis
000078348 260__ $$c2018
000078348 5060_ $$aAccess copy available to the general public$$fUnrestricted
000078348 5203_ $$aPatients with a first episode of psychosis (FEP) display a broad range of metabolic risk factors related to the development of diverse medical comorbidities. Initial stages of these disorders are essential in understanding the increased vulnerability of developing cardiometabolic disturbances, associated with a reduced life expectancy. This study aimed to evaluate the metabolic profile of a cohort of patients with a FEP and its evolution during a two year follow-up, as well as the factors that influence the changes in their metabolic status. 16 participating centers from the PEPs Project recruited 335 subjects with a FEP and 253 matched healthy controls, aged 9–35 years. We investigated a set of anthropometric measures, vital signs and laboratory data obtained from each participant over two years in a prospective, naturalistic study. From the beginning of the study the FEP group showed differences in the metabolic profile compared to the control group, together with a progressive worsening in the major part of the analyzed variables during the follow-up period, with higher rates of obesity and metabolic syndrome. Certain risk factors were related to determinate clinical variables such as male gender, the presence of affective symptoms or an early onset or to treatment variables such as the use of antipsychotic polypharmacy, antidepressants or mood stabilizers. Our results highlight the extremely high risk of patients at early phases of schizophrenia and other psychotic disorders of developing cardiovascular comorbidity and the fast worsening of the metabolic profile during the first two years.
000078348 536__ $$9info:eu-repo/grantAgreement/ES/FEDER/Una manera de hacer Europa$$9info:eu-repo/grantAgreement/ES/MINECO-ISCIII/PI-080208-PEPs study
000078348 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000078348 590__ $$a4.569$$b2018
000078348 591__ $$aPSYCHIATRY$$b19 / 142 = 0.134$$c2018$$dQ1$$eT1
000078348 591__ $$aPSYCHIATRY$$b25 / 146 = 0.171$$c2018$$dQ1$$eT1
000078348 592__ $$a2.168$$b2018
000078348 593__ $$aPsychiatry and Mental Health$$c2018$$dQ1
000078348 593__ $$aBiological Psychiatry$$c2018$$dQ1
000078348 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000078348 700__ $$aGarcía-Portilla, M.A.P.
000078348 700__ $$aGarcía-Rizo, C.
000078348 700__ $$aCabrera, B.
000078348 700__ $$0(orcid)0000-0002-9098-655X$$aLobo, A.$$uUniversidad de Zaragoza
000078348 700__ $$aGonzález-Pinto, A.
000078348 700__ $$aDíaz-Caneja, C.M.
000078348 700__ $$aCorripio, I.
000078348 700__ $$aVieta, E.
000078348 700__ $$aCastro-Fornieles, J.
000078348 700__ $$aBobes, J.
000078348 700__ $$aGutiérrez-Fraile, M.
000078348 700__ $$aRodriguez-Jimenez, R.
000078348 700__ $$aMezquida, G.
000078348 700__ $$aLlerena, A.
000078348 700__ $$aSaiz-Ruiz, J.
000078348 700__ $$aBernardo, M.
000078348 700__ $$aPEPs, GROUP
000078348 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000078348 773__ $$g193 (2018), 188-196$$pSchizophr. res.$$tSCHIZOPHRENIA RESEARCH$$x0920-9964
000078348 8564_ $$s1075051$$uhttps://zaguan.unizar.es/record/78348/files/texto_completo.pdf$$yPostprint
000078348 8564_ $$s105444$$uhttps://zaguan.unizar.es/record/78348/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000078348 909CO $$ooai:zaguan.unizar.es:78348$$particulos$$pdriver
000078348 951__ $$a2020-01-17-22:04:19
000078348 980__ $$aARTICLE